読み込み中
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
前日終値
$3.94
+$0.30 · +8.24%
日中の時刻はETです。市場データは遅延する場合があります。
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
日中レンジ
現在 $3.94
52週レンジ
現在 $3.94
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
27
割高
センチメント
52
まちまち
リスク
59
やや高いリスク
モメンタム
53
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
日中レンジ
現在 $3.94
52週レンジ
現在 $3.94
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 1429万 USD | 3657.1万 USD | 3213万 USD | 3173.7万 USD | 2381.8万 USD |
| 販売・一般管理 | 579.5万 USD | 586.2万 USD | 594.2万 USD | 661.5万 USD | 636.1万 USD |
| 営業費用 | 2008.5万 USD | 4243.3万 USD | 3807.2万 USD | 3835.2万 USD | 3017.9万 USD |
| 受取利息 | 12.6万 USD | 33.8万 USD | 23万 USD | 5.2万 USD | 3000 USD |
| 支払利息 | 732.9万 USD | 554万 USD | 279.2万 USD | 103.3万 USD | 48.9万 USD |
| 減価償却費と償却費 | 5.3万 USD | 3.7万 USD | 3.3万 USD | 3.2万 USD | 4.1万 USD |
| 営業利益 | −2008.5万 USD | −4243.3万 USD | −3807.2万 USD | −3835.2万 USD | −3017.9万 USD |
| 純利益 | −3083.6万 USD | −4704.7万 USD | −4106.6万 USD | −3877.6万 USD | −3052.7万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$11.00
上昇余地（179.19%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI600.97万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM439.69万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF246.28万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO112.36万0.01%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO108.81万0.01%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC54.71万0.04%13.17億 USD0.60%$183+0.11%
Horizon Kinetics Medical ETFMEDX16.73万1.01%1658.37万 USD0.85%$35.2935+1.71%
Vanguard Russell 2000 Growth ETFVTWG14.16万0.01%17億 USD0.06%$260.49+0.91%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCHorizon Kinetics Medical ETFMEDXVanguard Russell 2000 Growth ETFVTWGAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
